TAO Synergies, Inc.

TAO Synergies Inc. is a public company positioned at the intersection of biotechnology and digital finance. Originally established as Synaptogenix, Inc. in 2012 and rebranded in 2025, the company has historically operated as a biopharmaceutical developer, focusing on advancing Bryostatin-1, a therapeutic candidate for Alzheimer’s disease and several other neurodegenerative conditions, including Fragile X syndrome and Multiple Sclerosis, through clinical and preclinical stages. In mid-2025, TAO Synergies Inc. shifted its strategic direction to become the first pure-play public company dedicated to leveraging synergies between cryptocurrency and artificial intelligence (AI). The company's treasury strategy centers exclusively on acquiring and staking TAO, the native token of Bittensor—a blockchain network focused on decentralized machine learning and AI. This approach positions TAO Synergies Inc. at the forefront of both digital asset management and AI innovation, reflecting its commitment to capitalizing on the growth and integration of these rapidly evolving sectors within the broader financial and technological markets.